Ian Tannock Cautions About Adjuvant Treatment for High-Risk RCC
Current guidelines from the National Comprehensive Cancer Network for treatment of high-risk renal cell carcinoma (RCC) recommend the use of adjuvant pembrolizumab. However, the authors of a recent